Madrasin

Research use only, not for human use.

Madrasin is a potent and cell penetrant splicing inhibitor that interferes with the early stages of spliceosome assembly.

Madrasin is a potent and cell penetrant splicing inhibitor that interferes with the early stages of spliceosome assembly. Madrasin stalls spliceosome assembly at the A complex.(In Vitro):Madrasin (10-30 μM; 4-24 hours; HeLa cells) treatment inhibits the splicing of each of the RIOK3, BRD2, and Hsp40, MCL1, CCNA2, AURKA and p27 pre-mRNAs in both HeLa and HEK293 cells.Madrasin (10-30 μM; 4-24 hours; HeLa and HEK293 cells) treatment shows a dose- and time-dependent inhibitory effect on cell cycle progression.

Madrasin (10-30 μM; 4-24 hours; HeLa cells) treatment inhibits the splicing of each of the RIOK3, BRD2, and Hsp40, MCL1, CCNA2, AURKA and p27 pre-mRNAs in both HeLa and HEK293 cells.Madrasin (10-30 μM; 4-24 hours; HeLa and HEK293 cells) treatment shows a dose- and time-dependent inhibitory effect on cell cycle progression. RT-PCRCell Line:HeLa cellsConcentration:10 μM, 20 μM, or 30 μM Incubation Time:4 hours, 8 hours, or 24 hoursResult:Increased in inhibition of pre-mRNA splicing. Cell Cycle Analysis Cell Line:HeLa and HEK293 cells Concentration:10 μM, 20 μM, or 30 μMIncubation Time:4 hours, 8 hours, or 24 hoursResult:In the presence of 10 μM 8 hours after treatment, the proportion of cells in G2, M, and S phases increased, with a concomitant decrease in the number of G1 phase cells. This effect increased over time, with >40% of cells in G2 and M phase and >50% in S phase 24 hours.

——

DDD00107587 | Madrasin. RNA splicing inhibitor

Metabolic Enzyme/Protease

Transferase

Others

Cancer

——

374913-63-0

311.34

C16H17N5O2

>98% (HPLC)

H2O : < 0.1 mg/mL

O=c1[nH]c(Nc2nc(C)c3ccc(OC)cc3n2)nc(C)c1C

2-((7-Methoxy-4-methylquinazolin-2-yl)amino)-5,6-dimethylpyrimidin-4(3H)-one

(-20℃)

With Ice Pack

≥ 2 years